Extracorporeal CO2 Removal Devices: Global Strategic Business Report

Global Extracorporeal CO2 Removal Devices Market to Reach $137 Million by 2030

The global market for Extracorporeal CO2 Removal Devices estimated at US$85.7 Million in the year 2022, is projected to reach a revised size of US$137 Million by 2030, growing at a CAGR of 6% over the analysis period 2022-2030. Extracorporeal CO2 Machines, one of the segments analyzed in the report, is projected to record 6.7% CAGR and reach US$81.5 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Disposables segment is readjusted to a revised 5.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $25.4 Million, While China is Forecast to Grow at 5.5% CAGR

The Extracorporeal CO2 Removal Devices market in the U.S. is estimated at US$25.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$23.6 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Select Competitors (Total 44 Featured) -

• Aferetica Srl
• Alung Technologies, Inc.
• ESTOR S.P.A
• Getinge AB
• Medica SpA
• Medtronic PLC
• Xenios AG

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and the publisher's Research Platform
• Complimentary updates for one year